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Introduction Marfan syndrome (MFS) is an au‑
tosomal dominant disorder of connective tissue 
with a prevalence of 2 to 3:10,000 in the world‑
wide population.1 It is characterized by high‑
ly variable phenotypic manifestations, main‑
ly in the cardiovascular (thoracic aortic aneu‑
rysm and dissection, mitral valve prolapse), oc‑
ular (lens dislocation), and skeletal (overgrowth, 
pectus deformities, dolichostenomelia) sys‑
tems.2,3 MFS is mostly caused by mutations in 
the fibrillin‑1 (FBN1) gene located on chromosome 
15q21.1.4 FBN1 is approximately 200 kb long and 
consists of 66 exons, of which 65 are coding and 
span together about 8.6 kb. Fibrillin‑1 is a cyste‑
ine‑rich extracellular matrix glycoprotein, whose 
monomers aggregate to form microfibrils that 
cluster at the margins of maturing elastic fibers.4,5
About 1500 mutations of the FBN1 gene have 
been identified (HGMD Professional 2013.2; 
http://www.hgmd.org/) including point (single‑ 
‑nucleotide) or length (deletions/insertions) vari‑
ants, either changing the structure or the amount 
of protein that is produced or affecting splicing 
process, which may lead to abnormalities in 
fibrillin‑1 synthesis, secretion and/or matrix de‑
position.5 Approximately 25% of MFS cases are 
underlain by de‑novo mutations.1 It has been 
demonstrated that fibrillin‑1 microfibrils contrib‑
ute to the regulation of transforming growth fac‑
tor β (TGF‑β) superfamily activation; thus, loss 
of fibrillin‑1 integrity and its structural defects 
may promote abnormal activation of TGF‑β. By 
interaction with its cell surface receptor, active 
TGF‑β mediates Smad protein phosphorylation, 
which results in downstream transcriptional re‑
sponse with deleterious consequences in the form 
of MFS, such as developmental emphysema, myx‑
omatous changes of the mitral valve, aortic an‑
eurysm formation, skeletal muscle myopathy, or 
bone overgrowth.1
The clinical diagnosis of MFS is primarily based 
on the revised Ghent nosology.3 FBN1 molecular 
genetic testing, although not mandatory, is of 
great value in the diagnostic assessment.3,6 We re‑
port the first 2 Polish cases of MFS, in which 
a molecular analysis was performed leading to 
the identification of causal FBN1 mutation.
Case 1 A  24‑year‑old female patient (II‑2) 
(height, 169 cm; weight, 45 kg) has suffered 
from scoliosis >20% and pectus excavatum since 
childhood, and underwent correction surgery 
at the age of 11, when MFS was first suspected. 
At the beginning of 2013, she underwent aortic 
root and aortic valve replacement for an ascend‑
ing aortic aneurysm using the Bentall and De 
Bono procedure; on the same occasion, she also 
underwent mitral valve replacement. The opera‑
tion was performed because of a rapid increase 
in the sinus Valsalva diameter from 40 to 48 mm 
within 4 months, associated with aortic and mi‑
tral regurgitation (IIº). Her systemic score ac‑
cording to the Ghent criteria was 7/20 points 
and included the  ratio of the  length of out‑
stretched arms to the body height of >1.05, pos‑
itive thumb (Steinberg) and wrist (Walker–Mur‑
doch) signs, widening of the aortic root, arched 
palate, crowded teeth, and mitral valve prolapse. 
An ophthalmological examination provided nor‑
mal results. The proband’s brother (II‑1), who 
had no signs or symptoms of cardiac diseases, 
died at the age of 27 because of right testis can‑
cer. A 35‑year‑old half‑sister of the proband (II‑3) 
(shared mother) also underwent the Bentall and 
De Bono procedure for an ascending aorta an‑
eurysm (62 mm in diameter at Valsalva sinus). 
She had pectus carinatum deformity, myopia of 
–6 diopters (D), and mitral valve prolapse. She 
underwent surgery for inguinal hernia at the age 
of 18. The score of her phenotypic features was 
11/20 points. An ophthalmological examination 
including slit‑lamp examination provided normal 
results. Her 15‑year‑old son (III‑1) has an aortic 
diameter of 47 mm at the Valsalva sinus and is 
kept under strict cardiological surveillance. He is 
on β‑blocker therapy. Ophthalmological exami‑
nations revealed myopia (–6 D) and bilateral lens 
subluxation. The score of his phenotypic features 
is 8/20. Her 2‑year‑old daughter (III‑2) does not 
fulfill the Ghent criteria at present. The mother 
(I‑2) of the proband died at the age of 52 years due 
to a ruptured ascending aortic aneurysm. Genet‑
ic testing of FBN1 in relevant and available fam‑
ily members is planned.
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lead to a substantial truncation of the FBN1 pro‑
tein product.
To the best of our knowledge, this is the first 
description of Polish patients with MFS, in whom 
molecular diagnostics was performed providing 
further evidence for the clinically established di‑
agnosis. The c.7022_7023del is a novel, not previ‑
ously reported, causal MFS mutation. The second 
variant, c.2433C>A, was described for the first 
time in a Taiwanese MFS subject.7 Both mutations 
confirm the clinical diagnosis of MFS in our cases.
It is well known that mutations resulting in 
a premature termination undergo nonsense‑ 
‑mediated RNA decay preventing synthesis of 
the truncated protein. Therefore, for both muta‑
tions identified in our patients, haploinsufficiency 
is most likely the mechanism involved.8 However, 
in a dominant‑negative model, it is predicted that 
the production of truncated fibrillin‑1 monomers 
interferes with the assembly of normal mono‑
mers into extracellular microfibrils.9,10 On the oth‑
er hand, overexpression of mutant fibrillin‑1 has 
been shown not to interfere with microfibrils as‑
sembly in transgenic mice. Finally, another study 
in mice showed that truncated fibrillin‑1 does not 
interfere with assembly of microfibrils but rath‑
er exerts a dominant‑negative effect on the sta‑
bility of microfibrils and the lack of certain pro‑
tein domains owing to the fact that truncated 
fibrillin‑1 molecules may disturb the proper in‑
teraction between collagenous environment and 
microfibrils.11 However, the mechanism of how 
the truncation of fibrillin‑1 leads to the clinical 
picture of MFS needs to be further clarified.
It has been known that fibrillin‑1 shares a high 
degree of homology with latent TGF‑β binding 
proteins (LTBPs). This homology has prompt‑
ed the hypothesis that extracellular microfibrils 
might participate in the regulation of TGF‑β acti‑
vation. TGF‑β cytokines, secreted as large latent 
complexes consisting of mature cytokine, latency‑ 
‑associated peptide and 1 of 3 LTBPs, are connect‑
ed to extracellular microfibrils.1,12 This interaction 
has been proposed to suppress the release of free 
and active TGF‑β.1 Impaired microfibrils assem‑
bly and they deficiency would then result in an in‑
adequate matrix sequestration with consequent 
promiscuous TGF‑β activation and increased out‑
put of TGF‑β‑responsive genes. Studies in mouse 
models of MFS have shown that the application 
of TGF‑β‑neutralizing antibody reduces lung sep‑
tation, myxomatous changes of the valves, thick‑
ness of the aortic wall, and collagen deposition.5 It 
seems that TGF‑β antagonism might be a produc‑
tive treatment strategy for MFS.5
In conclusion, our report supports the view 
that FBN1 genetic testing should be conducted in 
patients with clinically suspected MFS. Molecular 
diagnosis could be a powerful tool for an individu‑
alized prognosis and management of this disease.
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Case 2 The proband, a 27‑year‑old male patient 
(height, 198 cm; weight, 96 kg), had his pectus ex‑
cavatum surgically corrected at the age of 11 years. 
In 2007, his 51‑year‑old father underwent a sur‑
gery for a ruptured ascending aorta aneurysm 
using the Bentall and De Bono procedure. Since 
then, the proband had strict cardiac follow‑up 
because of the strong suspicion of MFS. Owing 
to a rapid increase in the aortic diameter from 
45 to 50 mm at the sinus of Valsalva in 2012, 
he underwent valve sparing aortic root replace‑
ment using the David IV procedure 4 months 
later. He is treated with a β‑blocker. His system‑
ic score is 9/20 points, including the presence 
of pectus excavatum requiring surgery, the ra‑
tio of upper to lower segment of <0.86, the ra‑
tio of the length of outstretched arms to body 
height of >1.05, the current manifestation of 
the thumb (Steinberg) and wrist (Walker–Mur‑
doch) signs, and extending aortic root. The pa‑
tient also had high‑arched palate, crowded teeth, 
facial dysmorphia (specifically, dolichocephalia), 
down‑slanting palpebral fissures, mitral valve 
prolapse, and skin striae. A slight myopia of 
–0.75 D was observed. He is the only child. His 
mother died of the complications of cholecysti‑
tis at the age of 27 years. After obtaining written 
informed consent from both cases, genomic DNA 
was extracted from EDTA blood for the molecular 
analysis of the FBN1 gene, performed using poly‑
merase‑chain reaction amplification of all cod‑
ing exons and their flanking intronic sequences. 
Consequently, these amplicons were analyzed us‑
ing the Illumina’s sequencing‑by‑synthesis tech‑
nology (MiSeq personal sequencer). The pres‑
ence of the mutation reported here for the first 
time (see further) was then confirmed by Sanger 
sequencing starting from the original genomic 
DNA. Sequence NM_000 138.4 (http://www.ncbi.
nlm.nih.gov/nuccore/NM_000 138) was used as 
a reference, while the location of the mutations 
at the complementary DNA or protein level was 
numbered according to the Universal Mutation 
Database (http://www.umd.be/FBN1/).
In case 1, a heterozygous nonsense mutation 
(c.2433C>A; p.Cys811X) located in exon 20 was 
identified. This mutation interrupts the reading 
frame by a premature termination codon at posi‑
tion 811. Case 2 harbors a heterozygous deletion 
(c.7022_7023del; p.Thr2341ArgfsX25) in exon 57. 
This deletion creates a frame shift at codon 2341, 
and the new reading frame ends by a stop codon 
24 positions downstream. Both mutations thus 
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